Biocon's stock is trading at Rs. 374.15, a rise of 1.65 points or 0.44% from its last close of Rs. 372.50 on the BSE. The stock opened at Rs. 376.35 and fluctuated between a high of Rs. 378.60 and a low of Rs. 373.90. A total of 36,893 shares have been traded so far.

The 'A' group stock, with a face value of Rs. 5, reached a 52-week high of Rs. 395.65 on September 17, 2024, and a 52-week low of Rs. 217.50 on October 31, 2023. Over the past week, the stock's highest and lowest points were Rs. 381.85 and Rs. 363.70, respectively. The company’s current market capitalization stands at Rs. 44,722.35 crore.

Promoters hold 60.64% of the company’s shares, while institutional and non-institutional investors own 20.20% and 19.17%, respectively.

Biocon recently entered into a licensing and supply agreement with Tabuk Pharmaceutical Manufacturing Company, a subsidiary of Astra Industrial Group. This deal allows Tabuk to commercialize Biocon’s GLP-1 diabetes and chronic weight management products in select Middle Eastern countries. Biocon will handle product development and manufacturing, while Tabuk will manage registration, importation, and marketing in the region. The agreement also includes the possibility of expanding to other GLP products and a future tech transfer for localized manufacturing.

Biocon is India's largest biotechnology firm and a leading player in Asia, specializing in biopharmaceuticals and research services with a focus on offering affordable treatments for chronic diseases worldwide.